JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Preparation of (S)-(+)-Pranidipine by Optical Resolution
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Preparation of (S)-(+)-Pranidipine by Optical Resolution
Baek, Du-Jong; Yoon, Ji Hye; Kim, Moon-Sik;
  PDF(new window)
 Abstract
In this study, the effective preparation method of (S)-(+)-pranidipine, the active component of antihypertensive drug as a calcium channel blocker, was developed using optical resolution. The racemic monocarboxylic acid 5 obtained by the hydrolysis of (±)-pranidipine was mixed with optically active quinidine to form salts, and the insoluble diastereomeric salt was collected and successive treatment with base and acid furnished (R)-(-)-carboxylic acid 7. (S)-(+)-Pranidipine was prepared by esterification of this acid with cinnamyl alcohol, and the analysis by chiral HPLC showed 100% enantiomeric excess (ee). This process would be industrially very useful to prepare chiral (S)-(+)-pranidipine, since the use of strong base and anhydrous solvents, and ultra-low temperature condition were excluded in this process.
 Keywords
(S)-(+)-Pranidipine;Calcium channel blocker;Antihypertensive drug;Optical resolution;Enantiomeric excess;
 Language
Korean
 Cited by
 References
1.
Ioan, P.; Carosati, E.; Micucci, M.; Cruciani, G.; Broccatelli, F.; Zhorov, B.; Chiarini, A.; Budriesi, R. Curr. Med. Chem. 2011, 18, 4901. crossref(new window)

2.
Nakayama, N.; Ikezono, K.; Ohura, M.; Yabuuchi, Y. Arzneimittelforschung-Drug Res. 1993, 43, 1266.

3.
(a) Mori, T.; Takeuchi, T.; Ohura, M.; Miyakoda, G.; Fujiki, H.; Orito, K.; Yoshida, K.; Hirano, T.; Yamamura, Y.; Sumida,T.; Nakaya, Y.; Satake, H.; Hata, F. Mol. Cell. Biochem. 1998, 178, 335. crossref(new window)

4.
(b) Hirano, T.; Ohura, M.; Orito, K.; Fujiki, H.; Miyakoda, G.; Mori, T. Eur. J. Pharmacol. 1997, 324, 201. crossref(new window)

5.
(a) Franckowiak, G.; Bechem, M.; Schramm, M.; Thomas, G. Eur. J. Pharmacol. 1985, 114, 223. crossref(new window)

6.
(b) Williams, J. S.; Grupp, I. L.; Grupp, G.; Vaghy, P. L.; Dumont, L.; Schwartz, A. Biochem. Biophys. Res. Commun. 1985, 131, 13. crossref(new window)

7.
(c) Gjorstrup, P.; Harding, H.; Isaksson, R.; Westerlund, C. Eur. J. Pharmacol. 1986, 122, 357. crossref(new window)

8.
Hirano, T.; Mori, T.; Kido, M.; Toide, K.; Ohura, M.; Fujiki, H.; Orito, K.; Yoshida, K.; Ikezono, K.; Sumida, T.; Nakayama, N.; Yabuuchi, Y. Fundam. Clin. Pharmacol. 1999, 13, 650. crossref(new window)

9.
Fleckenstein, A. Circul. Res. 1983, 52, I3.

10.
Ahuja, S. Chiral Separation Methods for Pharmaceutical and Biotechnological Products; John Wiley & Sons: NewYork, U.S.A., 2011.

11.
Kadoiri, A.; Ikawa, H.; Kobayashi, N.; Isowa, Y. Optically active 1,4-dihydropyridine derivatives and methods of producing the same, JP 6,043,397B, Jun. 8, 1994.

12.
Ikawa, H.; Kadoiri, A.; Konagai, Y.; Yamaura, T.; Kase, N. 1,4-Dihydropyridine derivatives and methods of producing the same, U. S. Patent 5,763,614, Jun. 9, 1998.

13.
Kim, M.-S.; Ko, I. J. S-(+)-Pranidipine and methods of producing the same, KR Patent 10-0832659, May 20, 2008.

14.
Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923. crossref(new window)

15.
Shibanuma, T.; Iwanani, M.; Okuda, K.; Takenaka, T.; Murakami, M. Chem. Pharm. Bull. 1980, 28, 2809. crossref(new window)